Comparative effectiveness of phosphate binders in patients with chronic kidney disease: A systematic review and network meta-analysis

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Sekercioglu, Nigar ^a   Thabane, Lehana ^a,b,c,d   Díaz Martínez, Juan Pablo ^a   Nesrallah, Gihad ^e,f   Longo, Christopher J ^g   Busse, Jason W ^a,h   Akhtar Danesh, Noori ^a   Agarwal, Arnav ^f   Al Khalifah, Reem ⁱ   Iorio, Alfonso ^a   Guyatt, Gordon H ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e HUMBER RIVER REGIONAL HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CITRATE CALCIUM; FERRIC CITRATE; IRON; LANTHANUM CARBONATE; MAGNESIUM; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; SEVELAMER CARBONATE; SUCROFERRIC OXYHYDROXIDE; CHELATING AGENT; PHOSPHATE;

CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE MINERAL AND BONE DISORDER; COMPARATIVE EFFECTIVENESS; DIET RESTRICTION; DRUG EFFICACY; FOLLOW UP; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PHOSPHORUS RESTRICTED DIET; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SELECTION BIAS; SYSTEMATIC REVIEW; BLOOD; COMPARATIVE STUDY; FEMALE; MALE; PHASE 4 CLINICAL TRIAL (TOPIC); RENAL INSUFFICIENCY, CHRONIC;

CHELATING AGENTS; CLINICAL TRIALS, PHASE IV AS TOPIC; FEMALE; HOSPITALIZATION; HUMANS; MALE; PHOSPHATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84974777696     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0156891     Document Type: Review

References (76)

1. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of internal medicine. 2003; 139(2):137-47. Epub 2003/07/16. PMID: 12859163.
2. Moe SM. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. European Journal of Clinical Investigation. 2006; 36:51-62. doi: 10.1111/j.1365-2362.2006.01665.x PMID: 16884398
3. Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil R 3rd. Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med. 1979; 66(5):790-6. Epub 1979/05/01. PMID: 443254.
4. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000; 58(1):353-62. Epub 2000/07/08. doi: 10.1046/j.1523-1755.2000.00173.x PMID: 10886582.
5. Sanchez-Perales C, Vazquez Ruiz de Castroviejo E, Garcia-Cortes MJ, Biechy Mdel M, Gil-Cunquero JM, Borrego-Hinojosa J, et al. Valvular calcifications at the start of dialysis predict the onset of cardiovascular events in the course of follow-up. Nefrologia. 2015; 35(2):157-63. Epub 2015/08/25. PMID: 26300509.
6. Rebic D, Rasic S, Hamzic-Mehmedbasic A, Dzemidzic J, Kurtalic E. Valvular calcification and left ventricular modifying in peritoneal dialysis patients. Ren Fail. 2015:1-7. Epub 2015/08/15. PMID: 26275111.
7. Wilkieson TJ, Rahman MO, Gangji AS, Voss M, Ingram AJ, Ranganath N, et al. Coronary artery calcification, cardiovascular events, and death: a prospective cohort study of incident patients on hemodialysis. Can J Kidney Health Dis. 2015; 2:29. Epub 2015/08/14. doi: 10.1186/s40697-015-0065-6 PMID: 26269747; PubMed Central PMCID: PMCPMC4534029.
8. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31(4):607-17. Epub 1998/04/08. PMID: 9531176.
9. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol. 2006; 1(4):825-31. Epub 2007/08/21. doi: 10.2215/cjn.02101205 PMID: 17699293.
10. O'Seaghdha CM, Hwang SJ, Muntner P, Melamed ML, Fox CS. Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant. 2011; 26(9):2885-90. Epub 2011/02/05. doi: 10.1093/ndt/gfq808 PMID: 21292817; PubMed Central PMCID: PMCPMC3175050.
11. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007; 22(10):2909-16. Epub 2007/05/23. doi: 10.1093/ndt/gfm286 PMID: 17517792.
12. Cernaro V, Santoro D, Lacquaniti A, Costantino G, Visconti L, Buemi A, et al. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. International journal of nephrology and renovascular disease. 2016; 9:11-9. Epub 2016/02/20. doi: 10.2147/ijnrd.s78040 PMID: 26893577; PubMed Central PMCID: PMCPMC4749089.
13. Locatelli F, Del Vecchio L, Violo L, Pontoriero G. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert opinion on drug safety. 2014; 13(5):551-61. Epub 2014/04/08. doi: 10.1517/14740338.2014.907791 PMID: 24702470.
14. Cozzolino M, Funk F, Rakov V, Phan O, Teitelbaum I. Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide. Current drug metabolism. 2014; 15(10):953-65. Epub 2015/02/07. PMID: 25658128.
15. Lee CT, Wu IW, Chiang SS, Peng YS, Shu KH, Wu MJ, et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study. J Nephrol. 2015; 28(1):105-13. Epub 2014/05/21. doi: 10.1007/s40620-014-0108-6 PMID: 24840781.
16. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet (London, England). 2013; 382 (9900):1268-77. Epub 2013/07/23. doi: 10.1016/s0140-6736(13)60897-1 PMID: 23870817.
17. Group. KDIGOKCW. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter. 2013;(3: ):1-150.
18. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society Series A, (Statistics in Society). 2009; 172(1):137-59. Epub 2009/04/22. doi: 10.1111/j.1467-985X.2008.00552.x PMID: 19381330; PubMed Central PMCID: PMCPMC2667312.
19. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed). 2008; 336(7650):924-6. Epub 2008/04/26. doi: 10.1136/bmj.39489.470347.AD PMID: 18436948; PubMed Central PMCID: PMCPmc2335261.
20. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004; 328(7454):1490. Epub 2004/06/19. doi: 10.1136/bmj.328.7454.1490 PMID: 15205295; PubMed Central PMCID: PMCPMC428525.
21. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol. 2013; 66(2):158-72. Epub 2012/05/23. doi: 10.1016/j.jclinepi.2012.01.012 PMID: 22609141.
22. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. J Clin Epidemiol. 2011; 64(12):1294-302. Epub 2011/08/02. doi: 10.1016/j.jclinepi.2011.03.017 PMID: 21803546.
23. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of clinical epidemiology. 2011; 64(12):1283-93. Epub 2011/08/16. doi: 10.1016/j.jclinepi.2011.01.012 PMID: 21839614.
24. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Research Synthesis Methods. 2012; 3(2):161-76. doi: 10.1002/jrsm.57 PMID: 26062088
25. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. J Clin Epidemiol. 2011; 64(12):1277-82. Epub 2011/08/02. doi: 10.1016/j.jclinepi.2011.01.011 PMID: 21802904.
26. Lumley T. Network meta-analysis for indirect treatment comparisons. Statistics in medicine. 2002; 21 (16):2313-24. Epub 2002/09/05. doi: 10.1002/sim.1201 PMID: 12210616.
27. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014; 349:g5630. doi: 10.1136/bmj.g5630 PMID: 25252733
28. Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. Graphical Tools for Network Meta-Analysis in STATA. PLoS ONE. 2013; 8(10). doi: 10.1371/journal.pone.0076654 PMID: 24098547; PubMed Central PMCID: PMCPMC3789683.
29. Cosmai L, Gallieni M, Porta C. Renal toxicity of anticancer agents targeting HER2 and EGFR. J Nephrol. 2015; 28(6):647-57. doi: 10.1007/s40620-015-0226-9
30. Ng KP, Arnold J, Sharif A, Gill P, Townend JN, Ferro CJ. Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System. 2015; 16(3):599-613. doi: 10.1177/1470320315575849
31. Barreto DV, Barreto Fde C, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, et al. Phosphate binder impact on bone remodeling and coronary calcification - results from the BRiC study. Nephron Clinical practice. 2008; 110(4):c273-83. Epub 2008/11/13. doi: 10.1159/000170783 PMID: 19001830.
32. Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2015; 65(5):728-36. Epub 2014/12/04. doi: 10.1053/j.ajkd.2014.10.014 PMID: 25468387.
33. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney international. 2007; 71(5):438-41. Epub 2007/01/04. doi: 10.1038/sj.ki.5002059 PMID: 17200680.
34. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology: JASN. 2012; 23(8):1407-15. Epub 2012/07/24. doi: 10.1681/asn.2012030223 PMID: 22822075; PubMed Central PMCID: PMCPMC3402292.
35. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney international. 2002; 62(1):245-52. Epub 2002/06/26. doi: 10.1046/j.1523-1755.2002.00434.x PMID: 12081584.
36. de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2010; 25(11):3707-17. Epub 2010/06/10. doi: 10.1093/ndt/gfq292 PMID: 20530499; PubMed Central PMCID: PMCPmc2957591.
37. Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clinical journal of the American Society of Nephrology: CJASN. 2012; 7(3):487-93. Epub 2012/01/14. doi: 10.2215/cjn.03820411 PMID: 22241819.
38. Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2013; 62(4):771-8. Epub 2013/05/21. doi: 10.1053/j.ajkd.2013.03.023 PMID: 23684755.
39. Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney international. 2014; 86 (3):638-47. Epub 2014/03/22. doi: 10.1038/ki.2014.58 PMID: 24646861; PubMed Central PMCID: PMCPmc4150998.
40. Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2011; 57(3):422-31. Epub 2011/01/18. doi: 10.1053/j.ajkd.2010.10.055 PMID: 21239096.
41. Lee CT, Wu IW, Chiang SS, Peng YS, Shu KH, Wu MJ, et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study. Journal of nephrology. 2015; 28(1):105-13. Epub 2014/05/21. doi: 10.1007/s40620-014-0108-6 PMID: 24840781.
42. Lee YK, Choi HY, Shin SK, Lee HY. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study. Clinical nephrology. 2013; 79(2):136-42. Epub 2012/12/06. doi: 10.5414/cn107362 PMID: 23211335.
43. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. Journal of the American Society of Nephrology: JASN. 2015; 26(2):493-503. Epub 2014/07/26. doi: 10.1681/asn.2014020212 PMID: 25060056; PubMed Central PMCID: PMCPmc4310662.
44. Ohtake T, Kobayashi S, Oka M, Furuya R, Iwagami M, Tsutsumi D, et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study. Journal of cardiovascular pharmacology and therapeutics. 2013; 18 (5):439-46. Epub 2013/04/26. doi: 10.1177/1074248413486355 PMID: 23615577.
45. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2008; 51 (6):952-65. Epub 2008/04/22. doi: 10.1053/j.ajkd.2008.02.298 PMID: 18423809.
46. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney international. 2007; 72(10):1255-61. Epub 2007/09/07. doi: 10.1038/sj.ki.5002518 PMID: 17805238.
47. Sadek T, Mazouz H, Bahloul H, Oprisiu R, El Esper N, El Esper I, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an openlabel, randomized study. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2003; 18(3):582-8. Epub 2003/02/14. PMID: 12584283.
48. Suki WN. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. Journal of renal nutrition: the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2008; 18(1):91-8. Epub 2007/12/20. doi: 10.1053/j.jrn.2007.10.019 PMID: 18089452.
49. Takahara Y, Matsuda Y, Takahashi S, Shigematsu T. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial. Clinical nephrology. 2014; 82 (3):181-90. Epub 2014/08/01. PMID: 25079863.
50. Takei T, Otsubo S, Uchida K, Matsugami K, Mimuro T, Kabaya T, et al. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clinical practice. 2008; 108(4):c278-83. Epub 2008/04/25. doi: 10.1159/000127361 PMID: 18434749.
51. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton, Vic). 2011; 16(3):290-8. Epub 2011/02/24. doi: 10.1111/j.1440-1797.2010.01412.x PMID: 21342323.
52. Urena-Torres P, Prie D, Keddad K, Preston P, Wilde P, Wan H, et al. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial. BMC nephrology. 2014; 15:71. Epub 2014/06/03. doi: 10.1186/1471-2369-15-71 PMID: 24885942; PubMed Central PMCID: PMCPmc4107721.
53. Wada K, Wada Y. Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial. Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2014; 18(4):353-60. Epub 2014/01/15. doi: 10.1111/1744-9987.12153 PMID: 24417760.
54. Wilson R, Zhang P, Smyth M, Pratt R. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Current medical research and opinion. 2009; 25(12):3021-8. Epub 2009/10/23. doi: 10.1185/03007990903399398 PMID: 19845495.
55. Wuthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clinical journal of the American Society of Nephrology: CJASN. 2013; 8(2):280-9. Epub 2012/11/06. doi: 10.2215/cjn.08230811 PMID: 23124782; PubMed Central PMCID: PMCPmc3562865.
56. Xu J, Zhang YX, Yu XQ, Liu ZH, Wang LN, Chen JH, et al. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China. BMC nephrology. 2013; 14:29. Epub 2013/02/06. doi: 10.1186/1471-2369-14-29 PMID: 23379590; PubMed Central PMCID: PMCPmc3570485.
57. Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2014; 29(5):1053-60. Epub 2014/01/01. doi: 10.1093/ndt/gft483 PMID: 24376274.
58. Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clinical journal of the American Society of Nephrology: CJASN. 2014; 9(3):543-52. Epub 2014/01/11. doi: 10.2215/cjn.05170513 PMID: 24408120; PubMed Central PMCID: PMCPmc3944759.
59. Spasovski G. Advances in pharmacotherapy for hyperphosphatemia in renal disease. Expert Opin Pharmacother. 2015; 16(17):2589-99. doi: 10.1517/14656566.2015.1092521
60. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87(7):E10-7. Epub 2000/09/29. PMID: 11009570.
61. Lee WH, Hsu PC, Chu CY, Chen SC, Lee HH, Lee MK, et al. Estimated Glomerular Filtration Rate and Systolic Time Intervals in Risk Stratification for Increased Left Ventricular Mass Index and Left Ventricular Hypertrophy. Medicine. 2016; 95(10):e2917. Epub 2016/03/11. PMID: 26962788.
62. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation. 2008; 118(17):1748-57. Epub 2008/10/08. doi: 10.1161/circulationaha.108.783738 PMID: 18838561.
63. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 2004; 66(6):2293-9. Epub 2004/12/01. doi: 10.1111/j.1523-1755.2004.66015.x PMID: 15569318.
64. Jono S, Nishizawa Y, Shioi A, Morii H. Parathyroid hormone-related peptide as a local regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997; 17(6):1135-42. Epub 1997/06/01. PMID: 9194765.
65. Granata A, Clementi A, Virzi GM, Brocca A, de Cal M, Scarfia VR, et al. Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment. European journal of internal medicine. 2016. Epub 2016/03/11. doi: 10.1016/j.ejim.2016.02.019 PMID: 26961461.
66. System USRD. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD2013.
67. Zhai CJ, Yang XW, Sun J, Wang R. Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol. 2015; 47(3):527-35. doi: 10.1007/s11255-014-0876-x PMID: 25399356.
68. Bolland MJ, Grey A, Reid IR. Calcium supplements and cardiovascular risk: 5 years on. Therapeutic Advances in Drug Safety. 2013; 4(5):199-210. doi: 10.1177/2042098613499790. PMC4125316. PMID: 25114781
69. Chan CT, Lovren F, Pan Y, Verma S. Nocturnal haemodialysis is associated with improved vascular smooth muscle cell biology. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2009; 24(12):3867-71. Epub 2009/09/19. doi: 10.1093/ndt/gfp495 PMID: 19762602.
70. Kooienga L. Phosphorus balance with daily dialysis. Seminars in dialysis. 2007; 20(4):342-5. Epub 2007/07/20. doi: 10.1111/j.1525-139X.2007.00304.x PMID: 17635826.
71. Toussaint N, Boddington J, Simmonds R, Waldron C, Somerville C, Agar J. Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis. Hemodialysis international International Symposium on Home Hemodialysis. 2006; 10(3):280-6. Epub 2006/06/30. doi: 10.1111/j.1542-4758.2006.00109.x PMID: 16805890.
72. Wu HC, Lee LC, Wang WJ. Associations among time-average mineral values, mortality and cardiovascular events in hemodialysis patients. Renal failure. 2015; 37(10):343-53. Epub 2015/09/17. doi: 10.3109/0886022x.2015.1087862 PMID: 26375759.
73. Tagawa M, Hamano T, Nishi H, Tsuchida K, Hanafusa N, Fukatsu A, et al. Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study. PloS one. 2014; 9(12):e114678. Epub 2014/12/11. doi: 10.1371/journal.pone.0114678 PMID: 25494334; PubMed Central PMCID: PMCPmc4262415.
74. Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2015; 20(15):00633-2.
75. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69(11):1945-53. PMID: 16641930.
76. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011; 6(4):913-21. doi: 10.2215/CJN.06040710 PMID: 21454719.